Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics has announced that the first patient has been dosed in the Phase 3 pivotal cohort of the LIGHTHOUSE trial evaluating ATSN-201 for the treatment of X-linked retinoschisis.
American Association for the Advancement of Science Names 10 UF Faculty Fellows (UF News)
The American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the Science family of journals, has named 10 University of Florida faculty members to its 2025 AAAS Fellows.